NIKKEI 225
37,982.24 -832.32 (-2.14%) HANG SENG
17,848.87 -92.91 (-0.52%) CRUDE OIL
78.23 -0.22 (-0.28%) GOLD FUTURES
2,341.90 -7.20 (-0.31%) DOW
38,589.16 -57.94 (-0.15%) Bitcoin GBP
52,382.05 +234.70 (+0.45%)
BioNTech SE (22UA.F)
| Previous close | 88.35 |
| Open | 90.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 86.15 - 90.00 |
| 52-week range | 77.50 - 116.00 |
| Volume | |
| Avg. volume | 1,200 |
| Market cap | 20.918B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 184.68 |
| EPS (TTM) | 0.47 |
| Earnings date | 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 02 Jun 2022 |
| 1y target est | 334.89 |
- Yahoo Finance Video
FDA considers updating COVID boosters, Novavax stock reacts
The US Food and Drug Administration (FDA) is set to vote on recommendations for updated COVID-19 booster shots as the KP.2 variant strain begins to spread across the US. Yahoo Finance Health Reporter Anjalee Khemlani joins Market Domination to discuss the impact this is having on vaccine makers, particularly Novavax (NVAX), whose stock has shot up in Monday's session. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Luke Carberry Mogan.
Globe NewswireInvestigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic non-small cell lung cancer treated with a combination of acasunlimab and pembrolizumab every six weeksData from this ongoing Phase 2 study to inform the planned pivotal Phase 3 trial, which is expected to start before the end of 2024 COPENHAGEN, Denmark, and MAINZ, Germany, June 1, 2024 — Genmab A/S (
GlobeNewswireBioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in Africa, for AfricaCEPI to fund up to $145 million to support BioNTech in broadening the scope of the manufacturing facility in Kigali, Rwanda, aimed at addressing needs of African countries and in compliance with global standards Partnership intends to contribute to building a sustainable and resilient end-to-end African vaccine ecosystemBioNTech and CEPI commi
